We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
-0.37%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$5.75B
AUM Growth
-$41.8M
Cap. Flow
+$154M
Cap. Flow %
2.69%
Top 10 Hldgs %
69.08%
Holding
53
New
7
Increased
13
Reduced
8
Closed
7

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$253M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$146M
3
GLUE icon
Monte Rosa Therapeutics
GLUE
+$67.4M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$52.2M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$28.6M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$128M
2
TVTX icon
Travere Therapeutics
TVTX
+$31.2M
3
RLMD icon
Relmada Therapeutics
RLMD
+$20.5M
4
PMVP icon
PMV Pharmaceuticals
PMVP
+$17.9M
5
RLAY icon
Relay Therapeutics
RLAY
+$17.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNKD icon
26
MannKind Corp
MNKD
$1.27B
$47M 0.82%
8,630,000
+1,130,000
+15% +$4.9M
CBAY
27
DELISTED
Cymabay Therapeutics
CBAY
$44.9M 0.78%
10,300,000
– –
ISEE
28
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$40.5M 0.71%
6,425,000
-825,000
-11% -$5.32M
DCPH
29
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$39.1M 0.68%
1,068,000
+175,000
+20% +$6.78M
RLMD icon
30
Relmada Therapeutics
RLMD
$571M
$29.9M 0.52%
935,000
-590,000
-39% -$20.5M
AVDL
31
DELISTED
Avadel Pharmaceuticals
AVDL
$29.4M 0.51%
4,365,000
– –
PRAX icon
32
Praxis Precision Medicines
PRAX
$8.9B
$29.2M 0.51%
106,667
+234
+0.2% +$83.8K
DSGN icon
33
Design Therapeutics
DSGN
$849M
$26.4M 0.46%
1,468,318
– –
AMRN
34
Amarin Corp
AMRN
$302M
$26.3M 0.46%
300,000
– –
OLMA icon
35
Olema Pharmaceuticals
OLMA
$1.01B
$24.5M 0.43%
876,986
– –
ADVM
36
DELISTED
Adverum Biotechnologies
ADVM
$24.3M 0.42%
695,000
-105,000
-13% -$5.66M
MRUS
37
DELISTED
Merus
MRUS
$13.9M 0.24%
660,000
-5,000
-0.8% -$111K
RNAM
38
DELISTED
Avidity Biosciences
RNAM
$13.5M 0.23%
545,000
– –
FENC icon
39
Fennec Pharmaceuticals
FENC
$365M
$12.2M 0.21%
1,670,000
– –
GNCA
40
DELISTED
Genocea Biosciences, Inc.
GNCA
$11.9M 0.21%
5,084,184
– –
CNTA
41
DELISTED
Centessa Pharmaceuticals
CNTA
$11.1M 0.19%
+500,000
New +$11.8M
TNGX icon
42
Tango Therapeutics
TNGX
$4.69B
$9.1M 0.16%
800,000
– –
ADAP
43
DELISTED
Adaptimmune Therapeutics
ADAP
$8.62M 0.15%
2,024,400
-1,525,600
-43% -$7.4M
WHWK
44
Whitehawk Therapeutics
WHWK
$201M
$7.61M 0.13%
+300,000
New +$6.85M
APLS
45
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$3.36M 0.06%
+240,000
New +$12.4M
ALNY icon
46
CALL
Alnylam Pharmaceuticals
ALNY
$30.6B
$1.43M 0.02%
+150,000
New +$22M
BDTX icon
47
Black Diamond Therapeutics
BDTX
$103M
– –
-440,000
Closed -$10.7M
LKFT
48
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.71B
– –
-3,100
Closed -$239K
RLAY icon
49
Relay Therapeutics
RLAY
$4.29B
– –
-500,000
Closed -$17.3M
TVTX icon
50
Travere Therapeutics
TVTX
$5.84B
– –
-1,249,000
Closed -$31.2M
1
2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q2 2021 Portfolio in Review

As of Q2 2021, Avoro Capital Advisors held 53 positions worth $5.75B, down 0.72% from $5.79B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Avoro Capital Advisors's Q2 2021 filing shows 7 new, 13 increased, 8 reduced and 7 closed positions. Its largest new stake was Ascendis Pharma A/S: 1,900,000 shares worth $250M. The largest sale was Vertex Pharmaceuticals, an estimated $128M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier.

  • Avoro Capital Advisors's largest Q2 2021 buy was Ascendis Pharma A/S: 1,900,000 shares worth $250M.
  • Avoro Capital Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q2 2021, an estimated $52.2M increase.
  • Avoro Capital Advisors's biggest Q2 2021 reduction was Vertex Pharmaceuticals, cutting an estimated $128M.
  • Avoro Capital Advisors fully exited Travere Therapeutics in Q2 2021, selling an estimated $31.2M.
  • Avoro Capital Advisors's ten largest holdings make up 69% of its $5.75B portfolio in Q2 2021.
  • Avoro Capital Advisors opened 7 new positions and closed 7 in Q2 2021.
  • Avoro Capital Advisors's portfolio value fell 0.72% quarter-over-quarter to $5.75B.

Based on Avoro Capital Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.